Filing Flows › Health Care › Serina Therapeutics (SER)
Serina Therapeutics (SER) earnings and revenue breakdown
Latest: Q2 2025 · 10-Q filed Aug 11, 2025 · Serina Therapeutics (SER) Q2 2025 earnings results →
Q2 2025 Revenue up 155% year over year to $130K
Serina Therapeutics made $130K in Q2 2025 (+155% Y/Y). Operating margin n/m, net loss $6.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $130K in Q2 2025, up 155% year over year.
Operating costs exceeded revenue by $5.6M, an operating margin of -4280.8%. Total costs grew 45% against revenue growth of 155%. The fastest-growing cost line was Research & development (+98%). The quarter ended with a net loss of $6.5M. Minority interests bore $14K of it: to shareholders the quarter was a loss of $6.4M.
Operating cash flow was −$3.8M. Non-cash charges added back $16K of depreciation and amortization and $890K of share-based compensation. Working capital and other items added $1.8M. Capital expenditures of $46K exceeded it, leaving free cash flow of −$3.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2025 | 10-Q | Aug 11, 2025 | $130K | +155% | n/m | −$6.5M | −$3.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Serina Therapeutics
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).The Company’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline) and is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via easy-to-administer, long-acting subcutaneous injection.
In its own words, from its 10-K, filed Mar 25, 2026.
Serina Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +155% against the peers' median +10%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SER Serina Therapeutics | Q2 2025 | $130K | +155% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Serina Therapeutics 10-Q on SEC EDGAR · CIK 1708599 · Pharmaceutical Preparations
13F: who owns SER and who is buying
More on SER
History
Every quarter: Q2 2025 results